Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Phase 1 study of oxaliplatin and irinotecan in pediatric patients with refractory solid tumors: a children's oncology group study.

Cancer - 15 Apr 2009

McGregor Lisa M, Spunt Sheri L, Furman Wayne L, Stewart Clinton F, Schaiquevich Paula, Krailo Mark D, Speights Roseanne, Ivy Percy, Adamson Peter C, Blaney Susan M

Abstract excerpt

BACKGROUND: For this report, the authors estimated the maximum tolerated dose (MTD) and investigated the toxicities of oxaliplatin combined with irinotecan in children with refractory solid tumors. METHODS: Oxaliplatin was administered on Days 1 and 8 in combination with irinotecan on Days 1 through 5 and Days 8 through 12 of a 21-day cycle. An oral cephalosporin was administered daily to ameliorate...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Camptothecin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Administration Schedule

Share to Glucuronosyltransferase

Share to Irinotecan

Share to Neoplasms

Share to Organoplatinum Compounds

Share to Oxaliplatin

Source

Open in PubMed Open full text

Identifiers

PMID: 19170226
DOI: 10.1002/cncr.24175
PMCID: PMC2897817

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phase 1 study of oxaliplatin and irinotecan in pediatric patients with refractory solid tumors: a children's oncology group study.PMID 19170226Read ↗

Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors.Semantic proximity Read ↗

Reducing irinotecan-associated diarrhea in children.Semantic proximity Read ↗

Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: a new approach to neuroblastoma therapy consortium study.Semantic proximity Read ↗

UGT1A1 genotype-guided phase I study of irinotecan, oxaliplatin, and capecitabine.Semantic proximity Read ↗

Irinotecan and oxaliplatin combination as the first-line treatment for patients with advanced non-small cell lung cancer.Semantic proximity Read ↗

A Phase I Study of a Combination of Liposomal Irinotecan and Veliparib in Solid TumorsSemantic proximity Read ↗

Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma, or leukemiaSemantic proximity Read ↗

A phase I pharmacologic and pharmacogenetic trial of sequential 24-hour infusion of irinotecan followed by leucovorin and a 48-hour infusion of fluorouracil in adult patients with solid tumors.Semantic proximity Read ↗

Phase I pharmacokinetic, food effect, and pharmacogenetic study of oral irinotecan given as semisolid matrix capsules in patients with solid tumors.Semantic proximity Read ↗

A multicenter phase 1 study of PX-866 and cetuximab in patients with metastatic colorectal carcinoma or recurrent/metastatic squamous cell carcinoma of the head and neck.Semantic proximity Read ↗

[Safety and efficacy of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) in Chinese patients with advanced colorectal cancer].Semantic proximity Read ↗

Phase II study of gemcitabine in children with solid tumors of mesenchymal and embryonic originSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.